Premium
Daclizumab, an efficient treatment for steroid‐refractory acute graft‐ versus ‐host disease
Author(s) -
Bordigoni Pierre,
Dimicoli Sophie,
Clement Laurence,
Baumann Cédric,
Salmon Alexandra,
Witz Francis,
Feugier Pierre
Publication year - 2006
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2006.06321.x
Subject(s) - daclizumab , medicine , graft versus host disease , refractory (planetary science) , gastrointestinal tract , gastroenterology , disease , immunology , surgery , transplantation , tacrolimus , biology , astrobiology
Summary In a phase II study, daclizumab was given as single second‐line agent to 62 patients with steroid‐refractory acute graft‐ versus ‐host disease (aGVHD). Complete resolution of aGVHD was achieved in 68·8% of patients. This response rate was significantly associated with a lower number of involved organs and smaller extent of skin involvement. The 4‐year event‐free survival (EFS) was 54·6%. Grade ≥III aGVHD, ≥2 involved organs at baseline and patient age >18 years were independently associated with lower EFS. Daclizumab could be a suitable alternative treatment for aGVHD, particularly when limited to the skin or gastrointestinal tract.